Phase 1/2, Open-label Study of Bosutinib Administered in Combination With Capecitabine in Subjects With Solid Tumor and ErbB2 Negative Locally Advanced or Metastatic Breast Cancer.

Trial Profile

Phase 1/2, Open-label Study of Bosutinib Administered in Combination With Capecitabine in Subjects With Solid Tumor and ErbB2 Negative Locally Advanced or Metastatic Breast Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 07 Oct 2014

At a glance

  • Drugs Bosutinib (Primary) ; Capecitabine (Primary)
  • Indications Advanced breast cancer; Cholangiocarcinoma; Colorectal cancer; Glioblastoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Feb 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 02 Jun 2011 Actual patient no (32) added as reported by ClinicalTrials.gov.
    • 02 Jun 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top